Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: Effect of dopaminergic denervation and L-DOPA administration

Brain Research

Volumn 813, Issue 1, 1998, Pages 150-159

  Oh, Justin D ^a   Russell, David ^b   Vaughan, Christina L ^a   Chase, Thomas N ^a  

^a Experimental Therapeutics Branch   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

6 hydroxydopamine lesion; Basal ganglia; Genistein; Motor response alteration; NMDA antagonist; Parkinson's disease

Indexed keywords

ACEA 10 1244; DOPAMINE; GENISTEIN; LEVODOPA; MDL 100453; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OXIDOPAMINE; PHOSPHOTYROSINE; PROTEIN TYROSINE KINASE INHIBITOR; RECEPTOR SUBUNIT; TYROSINE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DENERVATION; DOPAMINERGIC SYSTEM; INTRACEREBRAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT;

ANIMALS; CORPUS STRIATUM; DENERVATION; DOPAMINE; DOPAMINE AGENTS; IMMUNOHISTOCHEMISTRY; LEVODOPA; MALE; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; PSYCHOMOTOR PERFORMANCE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0004521596     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(98)01049-X     Document Type: Article

References (70)

1. Blanchet P.J., Papa S.M., Metman L.V., Mouradian M.M., Chase T.N. Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease. Neurosci. Biobehav. Rev. 21:1997;447-453.
2. Blanchet P.J., Verhagen M.L., Mouradian M.M., Chase T.N. Acute pharmacologic blockade of dyskinesias in Parkinson's disease. Mov. Disord. 11:1996;580-581.
3. P.J. Blanchet, S. Konitsiotis, E.R. Whittemore, Z.L. Zhou, R.M. Woodward, T.N. Chase, Different NMDA receptor antagonists display opposite effects on dyskinesias in levodopa-primed MPTP monkeys, Ann. Neurol., 1988, submitted.
4. Blandini F., Greenamyre J.T. Prospects of glutamate antagonists in the therapy of Parkinson's disease. Fundam. Clin. Pharmacol. 12:1998;4-12.
5. Braunton J.L., Wong V., Wang W., Salter M.W., Roder J., Liu M., Wang Y.T. Reduction of tyrosine kinase activity and protein tyrosine dephosphorylation by anoxic stimulation in vitro. Neuroscience. 82:1998;161-170.
6. Bravi D., Mouradian M.M., Roberts J.W., Davis T.L., Shon Y.H., Chase T.N. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Ann. Neurol. 36:1994;27-31.
7. Carroll C.B., Holloway V., Brotchie J.M., Mitchell I.J. Neurochemical and behavioral investigations of the NMDA receptor-associated glycine site in the rat striatum-functional implications for treatment of parkinsonian symptoms. Psychopharmacology. 119:1995;55-65.
8. Cervo L., Samanin R. Effects of dopaminergic and glutamatergic receptor antagonists on the establishment and expression of conditioned locomotion to cocaine in rats. Brain Res. 731:1996;31-38.
9. Chase T.N. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drugs. 55:1998;1-9.
10. Chase T.N., Oh J.D., Blanchet P.J. Neostriatal mechanisms in Parkinson's disease. Neurology. 51:1998;S30-S35.
11. Chen S.J., Leonard J.P. Protein tyrosine kinase-mediated potentiation of currents from cloned NMDA receptors. J. Neurochem. 67:1996;194-200.
12. Danysz W., Parsons C.G., Kornhuber J., Schmidt W.J., Quack G. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents - preclinical studies. Neurosci. Biobehav. Rev. 21:1997;455-468.
13. Engber T.M., Anderson J.J., Boldry R.C., Kuo S., Chase T.N. N-Methyl-D-aspartate receptor blockade differentially modifies regional cerebral metabolic responses to D(1)-dopamine and D(2)-dopamine agonists in rats with a unilateral 6-hydroxydopamine lesion. Neuroscience. 54:1993;1051-1061.
14. Engber T.M., Anderson J.J., Boldry R.C., Papa S.M., Kuo S., Chase T.N. Excitatory amino acid receptor antagonists modify regional cerebral metabolic responses to levodopa in 6-hydroxydopamine lesioned rats. Neuroscience. 59:1994;389-399.
15. Engber T.M., Papa S.M., Boldry R.C., Chase T.N. NMDA receptor blockade reverses motor response alterations induced by levodopa. NeuroReport. 5:1994;2586-2588.
16. Gerfen C.R., Keefe K.A., Gauda E.B. D1 and D2 dopamine receptor function in the striatum: coactivation of D1- and D2-dopamine receptors on separate populations of neurons results in potentiated immediate early gene response in D1-containing neurons. J. Neurosci. 15:1995;8167-8176.
17. Gossel M., Schmidt W.J., Loscher W., Zajaczkowski W., Danysz W. Effect of coadministration of glutamate-receptor antagonists and dopaminergic agonists on locomotion in monoamine-depleted rats. J. Neural Transm. 10:1995;27-39.
18. Graybiel A.M., Aosaki T., Flaherty A.W., Kimura M. The basal ganglia and adaptive motor control. Science. 265:1994;1826-1831.
19. Greenamyre J.T., Eller R.V., Zhang Z.M., Ovadia A., Kurlan R., Gash D.M. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann. Neurol. 35:1994;655-661.
20. Gurd J.W. Protein tyrosine phosphorylation: implications for synaptic function. Neurochem. Int. 31:1997;635-649.
21. Hisatsune C., Umemori H., Inoue T., Michikawa T., Kohda K., Mikoshiba K., Yamamoto T. Phosphorylation-dependent regulation of N-methyl-D-aspartate receptors by calmodulin. J. Biol. Chem. 272:1997;20805-20810.
22. Hurtig H.I. Problems with current pharmacologic treatment of Parkinson's disease. Exp. Neurol. 144:1997;10-16.
23. Jin D.H., Jung Y.W., Ham S.H., Ko B.H., Moon I.S. Developmental expression, subcellular localization, and tyrosine phosphorylation of NR2A and NR2B in the rat brain. Mol. Cells. 7:1997;64-71.
24. Kanda T., Jackson M.J., Smith L.A., Pearce R.K.B., Nakamura J., Kase H., Kuwana Y., Jenner P. Adenosine A(2A) antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in Parkinsonian monkeys. Ann. Neurol. 43:1998;507-513.
25. Kohr G., Seeburg P.H. Subtype-specific regulation of recombinant NMDA receptor-channels by protein tyrosine kinases of the src family. J. Physiol. (London). 492:1996;445-452.
26. Kohr G., Sprengel R., Seeburg P.H. Importance of the intracellular domains of NR2 subunits in NMDA receptor function. Naunyn-Schmiederberg's Arch. Pharmacol. 357:1998;111.
27. Kojima N., Wang J., Mansuy I.M., Grant S.G.N., Mayford M., Kandel E.R. Rescuing impairment of long-term potentiation in fyn-deficient mice by introducing Fyn transgene. Proc. Natl. Acad. Sci. USA. 94:1997;4761-4765.
28. Kotter R. Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum. Prog. Neurobiol. 44:1994;163-196.
29. Lange K.W., Riederer P. Glutamatergic drugs in Parkinson's disease. Life Sci. 55:1994;2067-2075.
30. Lau I.F., Huganir R.L. Differential tyrosine phosphorylation of n-methyl-D-aspartate receptor subunits. J. Biol. Chem. 270:1995;20036-20041.
31. Leonard A.S., Hell J.W. Cyclic AMP-dependent protein kinase and protein kinase C phosphorylate N-methyl-D-aspartate receptors at different sites. J. Biol. Chem. 272:1997;12107-12115.
32. Lu Y.M., Roder J.C., Davidow J., Salter M.W. Src activation in the induction of long-term potentiation in CA1 hippocampal neurons. Science. 279:1998;1363-1367.
33. Marin C., Papa S.M., Engber T.M., Bonastre M., Tolosa E., Chase T.N. MK801 prevents levodopa-induced motor response alterations in parkinsonian rats. Brain Res. 736:1996;202-205.
34. Menegoz M., Lau L.F., Herve D., Huganir R.L., Girault J.A. Tyrosine phosphorylation of NMDA receptor in rat striatum: effect of 6-OHDA dopamine lesions. NeuroReport. 7:1995;125-128.
35. Metman L.V., Blanchet P.J., Mouradian M.M., Chase T.N. Dextromethorphan and levodopa combination therapy in Parkinson's patients with response fluctuations. Mov. Disord. 11:1996;184.
36. Metman L.V., Del Dotto P., Blanchet P.J., van den Munckhof P., Chase T.N. Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Amino Acids. 14:1998;75-82.
37. Metman L.V., Del Dotto P., van den Munckhof P., Fang J., Mouradian M.M., Chase T.N. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology. 50:1998;1323-1326.
38. Metman L.V., Locatelli E.R., Bravi D., Mouradian M.M., Chase T.N. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications. Neurology. 50:1998;574.
39. Mitchell I.J., Carroll C.B. Reversal of parkinsonian symptoms in primates by antagonism of excitatory amino acid transmission: potential mechanisms of action. Neurosci. Biobehav. Rev. 21:1997;469-475.
40. Miyakawa T., Yagi T., Kitazawa H., Yasuda M., Kawai N., Tsuboi K., Niki H. Fyn-kinase as a determinant of ethanol sensitivity: relation to NMDA-receptor function. Science. 278:1997;698-701.
41. Monyer H., Sprengel R., Schoepfer R., Herb A., Higuchi M., Lomeli H., Burnashev N., Sakmann B., Seeburg P.H. Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science. 256:1992;1217-1221.
42. 2+ calmodulin-dependent protein-kinase-II. Mol. Cells. 5:1995;475-480.
43. Mori A., Shindou T., Ichimura M., Nonaka H., Kase H. The role of adenosine A(2a) receptors in regulating GABAergic synaptic transmission in striatal medium spiny neurons. J. Neurosci. 16:1996;605-611.
44. Nestler E.J. Molecular neurobiology of drug-addiction. Neuropsychopharmacology. 11:1994;77-87.
45. Odell T.J., Kandel E.R., Grant S.G.N. Long-term potentiation in the hippocampus is blocked by tyrosine kinase inhibitors. Nature. 353:1991;558-560.
46. Oh J.D., Del Dotto P., Chase T.N. Protein kinase A inhibitor attenuates levodopa-induced motor response alterations in the hemi-parkinsonian rat. Neurosci. Lett. 228:1997;5-8.
47. Papa S.M., Boldry R.C., Engber T.M., Kask A.M., Chase T.N. Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Res. 701:1995;13-18.
48. Papa S.M., Chase T.N. Levodopa-induced dyskinesia improved by a glutamate antagonist in Parkinsonian monkeys. Ann. Neurol. 39:1996;574-578.
49. Papa S.M., Engber T.M., Kask A.M., Chase T.N. Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res. 662:1994;69-74.
50. Parent A., Cicchetti F. The current model of basal ganglia organization under scrutiny. Mov. Disord. 13:1998;199-202.
51. Raymond L.A., Tingley W.G., Blackstone C.D., Roche K.W., Huganir R.L. Glutamate-receptor modulation by protein-phosphorylation. J. Physiol. (Paris). 88:1994;181-192.
52. Rosenblum K., Berman D.E., Hazvi S., Lamprecht R., Dudai Y. NMDA receptor and the tyrosine phosphorylation of its 2B subunit in taste learning in the rat insular cortex. J. Neurosci. 17:1997;5129-5135.
53. Rosenblum K., Dudai Y., Levin G.R. Long-term potentiation increases tyrosine phosphorylation of the N-methyl-D-aspartate receptor subunit 2B in rat dentate gyrus in vivo. Proc. Natl. Acad. Sci. USA. 93:1996;10457-10460.
54. Rostas J.A.P., Brent V.A., Voss K., Errington M.L., Bliss T.V.P., Gurd J.W. Enhanced tyrosine phosphorylation of the 2B subunit of the N-methyl-D-aspartate receptor in long-term potentiation. Proc. Natl. Acad. Sci. USA. 93:1996;10452-10456.
55. Schultz W. Behavior-related activity of primate dopamine neurons. Rev. Neurol. (Paris). 150:1994;634-639.
56. Seasack S.R., Aoki C., Pickel V.M. Ultrastructural localization of D2-receptor-like immunoreactivity in midbrain dopamine neurons and their striatal targets. J. Neurosci. 14:1994;88-106.
57. Sigel E. Functional modulation of ligand-gated gaba(a) and NMDA receptor channels by phosphorylation. J. Recept. Signal Transduction Res. 15:1995;325-332.
58. Smith Y., Shink E., Sidibe M. Neuronal circuitry and synaptic connectivity of the basal ganglia. Neurosurg. Clin. North Am. 9:1998;203.
59. Smith A.D., Bolam J.P. The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurons. Trends. Neurosci. 13:1990;259-265.
60. Standaert D.G., Testa C.M., Young A.B., Penney J.B. Organization of N-methyl-D-aspartate glutamate-receptor gene-expression in the basal ganglia of the rat. J. Comp. Neurol. 343:1994;1-16.
61. Stefani A., Pisani A., Bernardi G., Bonci A., Mercuri N.B., Stratta F., Calabresi P. The modulation of dopamine receptors in rat striatum. J. Neural Transm. Suppl. 45:1995;61-66.
62. Suzuki T., Okumura-Noji K. NMDA receptor subunits epsilon 1 (NR2A) and epsilon 2 (NR2B) are substrates for Fyn in the postsynaptic density fraction isolated from the rat brain. Biochem. Biophys. Res. Commun. 216:1995;582-588.
63. Takagi N., Shinno K., Teves L., Bissoon N., Wallace M.C., Gurd J.W. Transient ischemia differentially increases tyrosine phosphorylation of NMDA receptor subunits 2A and 2B. J. Neurochem. 69:1997;1060-1065.
64. Tingley W.G., Ehler M.D., Kameyama K., Doherty C., Ptak J.B., Riley C.T., Huganir R.L. Characterization of protein kinase A and protein kinase C phosphorylation of the N-methyl-D-aspartate receptor NR1 subunit using phosphorylation site-specific antibodies. J. Biol. Chem. 272:1997;5157-5166.
65. Ulas J., Cotman C. Dopaminergic denervation of striatum results in elevated expression of NR2A subunit. NeuroReport. 7:1996;1789-1793.
66. Wang Y.T., Salter M.W. Regulation of NMDA receptors by tyrosine kinases and phosphatases. Nature. 369:1994;233-235.
67. Whitechurch R.A., Ng K.T., Sedman G.L. Tyrosine kinase inhibitors impair long-term memory formation in day-old chicks. Cogn. Brain Res. 6:1997;115-120.
68. Wickens J.R., Kotter R., Alexander M.E. Effects of local connectivity on striatal function - stimulation and analysis of a model. Synapse. 20:1995;281-298.
69. Yu X.M., Askalan R., Keil G.J., Salter M.W. NMDA channel regulation by channel-associated protein tyrosine kinase Src. Science. 275:1997;674-678.
70. Z.L. Zhou, S.X. Cai, P.W. Yuen, L.D. Wise, E.R. Whittemore, C.S. Konkoy, R.M. Woodward, Synthesis and SAR of 4-benzyl-4-hydroxy-N-(hydroxyphenylalkyl)-piperidines as subtype selective NMDA receptor antagonists, Am. Chem. Soc., 1998, in press.